Search Results - "Giles, F. J."

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia by Giles, F J, O'Dwyer, M, Swords, R

“…Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that…”
Get full text

Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lymphoma by Kennedy, M P, Jimenez, C A, Bruzzi, J F, Mhatre, A D, Lei, X, Giles, F J, Fanning, T, Morice, R C, Eapen, G A

“…The diagnostic accuracy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of lymphoma in patients with…”
Get more information

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results by le Coutre, P D, Giles, F J, Hochhaus, A, Apperley, J F, Ossenkoppele, G J, Blakesley, R, Shou, Y, Gallagher, N J, Baccarani, M, Cortes, J, Kantarjian, H M

“…Nilotinib (Tasigna) is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic…”
Get full text

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma by HARITUNIANS, T, MORI, A, O'KELLY, J, LUONG, Q. T, GILES, F. J, KOEFFLER, H. P

“…Mantle cell lymphoma (MCL) is an aggressive form of B-cell non-Hodgkin's lymphoma, with a mean survival of only 3-5 years and suboptimal therapeutic options…”
Get full text

Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism by Zhang, H, Trachootham, D, Lu, W, Carew, J, Giles, F J, Keating, M J, Arlinghaus, R B, Huang, P

“…Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically…”
Get full text

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase by Giles, F J, Kantarjian, H M, le Coutre, P D, Baccarani, M, Mahon, F-X, Blakesley, R E, Gallagher, N J, Gillis, K, Goldberg, S L, Larson, R A, Hochhaus, A, Ottmann, O G

“…Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and imatinib-resistant or -intolerant patients with chronic myeloid leukemia…”
Get full text

Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells by XU, R.-H, PELICANO, H, ZHANG, H, GILES, F. J, KEATING, M. J, HUANG, P

“…The mammalian target of rapamycin (mTOR) pathway plays important roles in regulating nutrient metabolism and promoting the growth and survival of cancer cells,…”
Get full text

Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia by O'BRIEN, Susan M, KANTARJIAN, Hagop, THOMAS, Deborah A, GILES, Francis J, FREIREICH, Emil J, CORTES, Jorge, LERNER, Susan, KEATING, Michael J

“…To conduct a dose-escalation trial of rituximab in patients with chronic lymphocytic leukemia (CLL) to define the maximum-tolerated dose (MTD), to evaluate…”
Get full text

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy by Giles, F J, Abruzzese, E, Rosti, G, Kim, D-W, Bhatia, R, Bosly, A, Goldberg, S, Kam, G L S, Jagasia, M, Mendrek, W, Fischer, T, Facon, T, Dünzinger, U, Marin, D, Mueller, M C, Shou, Y, Gallagher, N J, Larson, R A, Mahon, F-X, Baccarani, M, Cortes, J, Kantarjian, H M

“…Nilotinib is a highly selective Bcr–Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML). Nilotinib and dasatinib, a multi-targeted…”
Get full text

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia by Lancet, J E, Ravandi, F, Ricklis, R M, Cripe, L D, Kantarjian, H M, Giles, F J, List, A F, Chen, T, Allen, R S, Fox, J A, Michelson, G C, Karp, J E

“…This study of vosaroxin evaluated dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics (PK), clinical activity and pharmacodynamics in…”
Get full text

Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database by Florek, A.G., Nardone, B., Thareja, S., Tran, G., Giles, F.J., West, D.P.

Get full text

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy by TSIMBERIDOU, A-M, KANTARJIAN, H. M, KEATING, M. J, BITAR, M. A, O'BRIEN, S, GILES, F. J, ESTEY, E, CORTES, J. E, VERSTOVSEK, S, FADERL, S, THOMAS, D. A, GARCIA-MANERO, G, FERRAJOLI, A, MANNING, J. T

“…Granulocytic sarcoma (GS) is an extramedullary tumor composed of immature myeloid cells. The objectives of this study were to describe the frequency,…”
Get full text

Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies by Giles, F J, Vey, N, Rizzieri, D, Ravandi, F, Prebet, T, Borthakur, G, Jacobsen, T F, Hagen, S, Nilsson, B, O'Brien, S

Get full text

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance by Toner, A P, McLaughlin, F, Giles, F J, Sullivan, F J, O'Connell, E, Carleton, L A, Breen, L, Dunne, G, Gorman, A M, Lewis, J D, Glynn, S A

“…Background: Taxanes are routinely used for the treatment of prostate cancer, however the majority of patients eventually develop resistance. We investigated…”
Get full text

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma by Mahalingam, D, Espitia, C M, Medina, E C, Esquivel, J A, Kelly, K R, Bearss, D, Choy, G, Taverna, P, Carew, J S, Giles, F J, Nawrocki, S T

“…Background: Upregulation of PIM kinase expression has been reported in many malignancies, suggesting that inhibition of PIM kinase activity may be an…”
Get full text

Phase 1 study of PTK787 ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome by ROBOZ, G. J, GILES, F. J, LAURENT, D, FELDMAN, E. J, LIST, A. F, CORTES, J. E, CARLIN, R, KOWALSKI, M, BILIC, S, MASSON, E, ROSAMILIA, M, SCHUSTER, M. W

“…PTK787/ZK 222584 (PTK/ZK) is an oral angiogenesis inhibitor targeting vascular endothelial growth factor (VEGF) receptor tyrosine kinases, including…”
Get full text

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study by Hochhaus, A, Masszi, T, Giles, F J, Radich, J P, Ross, D M, Gómez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, García-Gutiérrez, V, Gattermann, N, Wiktor-Jedrzejczak, W, le Coutre, P D, Martino, B, Saussele, S, Menssen, H D, Deng, W, Krunic, N, Bedoucha, V, Saglio, G

“…The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after…”
Get full text

Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia by KANTARJIAN, H. M, O'BRIEN, S, HA, C. S, KEATING, M. J, MURPHY, S, FREIREICH, E. J, SMITH, T. L, CORTES, J, GILES, F. J, BERAN, M, PIERCE, S, HUH, Y, ANDREEFF, M, KOLLER, C

“…To evaluate the efficacy and toxicity of Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), a dose-intensive regimen, in…”
Get full text

Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia by O'BRIEN, Susan M, KANTARJIAN, Hagop M, CORTES, Jorge, BERAN, Miloslav, KOLLER, Charles A, GILES, Francis J, LERNER, Susan, KEATING, Michael

“…To assess the efficacy of combination therapy with fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia (CLL) based on data…”
Get full text

Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes by YAZJI, S, GILES, F. J, TSIMBERIDOU, A-M, ESTEY, E. H, KANTARJIAN, H. M, O'BRIEN, S. A, KURZROCK, R

“…The purpose of this study was to determine the efficacy of and tolerance to antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic…”
Get full text